Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 2
1971 2
1972 2
1973 6
1974 5
1975 2
1977 2
1978 4
1979 2
1980 3
1981 1
1982 1
1983 2
1984 1
1985 1
1986 1
1987 2
1988 2
1989 5
1990 5
1991 5
1992 2
1993 2
1994 3
1995 2
1996 6
1997 2
1998 4
1999 1
2000 3
2001 6
2002 4
2003 4
2004 4
2005 6
2006 9
2007 5
2008 6
2009 3
2010 10
2011 13
2012 12
2013 9
2014 9
2015 5
2016 4
2017 7
2018 10
2019 4
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

201 results
Results by year
Filters applied: . Clear all
Page 1
Optimal route of diphtheria toxin administration to eliminate native nephron progenitor cells in vivo for kidney regeneration.
Fukunaga S, et al. Biochem Biophys Res Commun 2018. PMID 29408475
To address the lack of organs for transplantation, we previously developed a method for organ regeneration in which nephron progenitor cell (NPC) replacement is performed via the diphtheria toxin receptor (DTR) system. ...For applications to natural models, such as animal fetuses, it is necessary to determine the optimal administration route and dose of DT. ...
To address the lack of organs for transplantation, we previously developed a method for organ regeneration in which nephron progenitor cell …
Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
Cheung LS, et al. Proc Natl Acad Sci U S A 2019. PMID 30718426 Free PMC article.
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25-positive cells including regulatory T cells and has been approved for the treatment of persistent or recurrent cutaneous T cell lymphoma. ...In a sequential dual-therapy study in tumors that have progressed for 10 days, both s-DAB-IL-2(V6A) and s-DAB-IL-2 given before checkpoint inhibition with anti-programmed cell death-1 (anti-PD-1) antibodies inhibited tumor growth, while either drug given as monotherapy had less effect. s-DAB-IL-2(V6A), a fully monomeric protein with reduced vascular leak, is a second-generation diphtheria-toxin-based fusion protein with promise as a cancer immunotherapeutic both alone and in conjunction with PD-1 blockade....
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25-positive cells including r …
Tagraxofusp: First Global Approval
Syed YY. Drugs 2019 - Review. PMID 30859413
Tagraxofusp (tagraxofusp-erzs) [Elzonris™] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). ...
Tagraxofusp (tagraxofusp-erzs) [Elzonris™] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a …
Efferocytosis of apoptotic alveolar epithelial cells is sufficient to initiate lung fibrosis
Kim KK, et al. Cell Death Dis 2018. PMID 30333529 Free PMC article.
We have previously shown that targeting the type II alveolar epithelium for injury by repetitively administering diphtheria toxin to transgenic mice expressing the diphtheria toxin receptor off of the surfactant protein C promoter (SPC-DTR) develop lung fibrosis, confirming that AEC injury is sufficient to cause fibrosis. In the present study, we find that SPC-DTR mice develop increased activation of caspase 3/7 after initiation of diphtheria toxin treatment consistent with apoptosis within AECs. ...
We have previously shown that targeting the type II alveolar epithelium for injury by repetitively administering diphtheria toxin
A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
McNeela EA, et al. Vaccine 2000. PMID 11137256
In this study, we examined the cellular and humoral immune responses in mice generated after both parenteral and mucosal immunizations with cross-reacting material (CRM(197)) of diphtheria toxin. ...Furthermore, intranasal immunization with CRM(197) and chitosan induced protective antibodies against the toxin in a guinea pig passive challenge model. ...
In this study, we examined the cellular and humoral immune responses in mice generated after both parenteral and mucosal immunizations with …
Diphtheria toxin and related proteins: effect of route of injection on toxicity and the determination of cytotoxicity for various cultured cells.
Pappenheimer AM, et al. J Infect Dis 1982. PMID 6798133
The effect of route of injection on the toxicity of intact diphtheria toxin, cross-reacting material (CRM45), and diphtherial fragment A was compared in several animal species. ...The cytotoxic dose od CRM45 was approximately 10(-7) M for a variety of cell lines derived from toxin-sensitive or toxin-resistant species. ...
The effect of route of injection on the toxicity of intact diphtheria toxin, cross-reacting material (CRM45), and diphtherial …
Myofibroblasts acquire retinoic acid-producing ability during fibroblast-to-myofibroblast transition following kidney injury
Nakamura J, et al. Kidney Int 2019. PMID 30661714 Free article.
We generated a novel mouse model expressing diphtheria toxin receptor on renal fibroblasts to allow for the selective disruption of renal fibroblast function. Administration of diphtheria toxin induced upregulation of the tubular injury marker Ngal and caused tubular proliferation in healthy kidneys, whereas administration of diphtheria toxin attenuated tubular regeneration in fibrotic kidneys. ...
We generated a novel mouse model expressing diphtheria toxin receptor on renal fibroblasts to allow for the selective disrupti …
Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits.
Caglar K, et al. APMIS 2005. PMID 15865606
Monophosphoryl lipid A (MPL) was evaluated for its ability to enhance the antibody response to diphtheria toxin and its fragment A and fragment B subunits. ...Two weeks after the second immunization, sera were obtained from the mice and analysed for antibody response to diphtheria toxin and its subunits. ...
Monophosphoryl lipid A (MPL) was evaluated for its ability to enhance the antibody response to diphtheria toxin and its fragme …
Adjuvant effect of diphtheria toxin after mucosal administration in both wild type and diphtheria toxin receptor engineered mouse strains.
Chapman TJ and Georas SN. J Immunol Methods 2013. PMID 24200744 Free PMC article.
The finding that murine and simian cells have differential susceptibility to diphtheria toxin (DTx) led to the development of genetically engineered mouse strains that express the simian or human diphtheria toxin receptor (DTR) under the control of various mouse gene promoters. ...Intratracheal administration of DTx resulted in robust depletion of lung Foxp3+ cells. However, DTx administration was accompanied by significant local inflammation, even in control C57Bl/6 mice. ...
The finding that murine and simian cells have differential susceptibility to diphtheria toxin (DTx) led to the development of …
201 results
Jump to page
Feedback